Radforsk Investment Foundation has granted five research projects a total amount of NOK 4,95 million to further develop exciting research projects within photodynamic treatment and photochemical internalization. Cancer researcher Pål Selbo receives NOK 3,75 million for his project.
Radforsk Investment Foundation is an evergreen investor focusing on companies that develop cancer treatment.
“Radforsk has invested NOK 205 million of its profit back into cancer research at Oslo University Hospital. Of these, NOK 32 million, have gone to research in PDT/PCI. This year, we grant five projects a total of NOK 4,95 million,” says Jónas Einarsson, CEO of Radforsk Investment Foundation.
Radforsk had received a total of six applications by the deadline of 15 January 2021. The applications have been assessed by external experts.
This year, one of the projects has been awarded a total of NOK 3,75 million over three years. It is a project led by researcher Pål Selbo at the Department of Cancer Research entitled “Novel Photobiological Strategies Counteracting Tumor Immune Escape”.
“This is exciting research aiming to apply PCI technology in the field of immunotherapy. Pål has extensive experience as a researcher in the field, so it’s fun that he went all the way to the top with this application,” says Einarsson.
“It is fantastic and very motivating to receive such great support from Radforsk. This means that I can finally realize this project,” says Pål Selbo.
The researchers who have received funding for PDT/PCI research in 2021 are:
- Anette Weyergang
- Beáta Grallert
- Mouldy Sioud
- Pål Selbo
- Petras Juzenas
Cancer research in the field of photodynamic therapy and photochemical internalisation studies the use of light in direct cancer treatment in combination with drugs, or to deliver drugs that can treat cancer to cells or organs.